Drug Use And Severe Outcomes Among Patients Hospitalized With Influenza Over Three Seasons by Parisi, Christina Elizabeth
Yale University 
EliScholar – A Digital Platform for Scholarly Publishing at Yale 
Public Health Theses School of Public Health 
January 2020 
Drug Use And Severe Outcomes Among Patients Hospitalized 
With Influenza Over Three Seasons 
Christina Elizabeth Parisi 
christina.parisi@yale.edu 
Follow this and additional works at: https://elischolar.library.yale.edu/ysphtdl 
Recommended Citation 
Parisi, Christina Elizabeth, "Drug Use And Severe Outcomes Among Patients Hospitalized With Influenza 
Over Three Seasons" (2020). Public Health Theses. 1980. 
https://elischolar.library.yale.edu/ysphtdl/1980 
This Open Access Thesis is brought to you for free and open access by the School of Public Health at EliScholar – 
A Digital Platform for Scholarly Publishing at Yale. It has been accepted for inclusion in Public Health Theses by an 
authorized administrator of EliScholar – A Digital Platform for Scholarly Publishing at Yale. For more information, 
please contact elischolar@yale.edu. 
1 
 
Drug use and severe outcomes among 







A thesis submitted in partial fulfillment of the requirements for the degree of  
Master of Public Health, Epidemiology of Microbial Diseases 








First Reader: Dr. James Hadler 




I could not have done this without the help of my advisers, Dr. James Hadler and Ms. 
Kimberly Yousey-Hindes. I would like to also thank my contacts at the Centers for Disease 
Control and Prevention, including Ms. Rachel Holstein, Ms. Alissa O’Halloran, and Ms. 
Shikha Garg, and my mentors at the Connecticut Emerging Infections Program at Yale 
School of Public Health, including Ms. Amber Maslar and Mr. James Meek. Thank you also 
to Dr. Linda Niccolai for advising me throughout the MPH program and throughout this 
project, and to Dr. Luke Davis and the Davis Lab Group for their guidance and feedback. 




















Influenza is a significant public health problem in the United States and around the 
world, causing considerable morbidity and mortality annually. Drug use is also a significant 
issue that is associated with numerous health complications and conditions. However, the 
relationship between severe influenza outcomes and drug use is not well understood. The 
objectives of this investigation are to compare the prevalence of demographic and behavioral 
factors associated with severe influenza outcomes between persons who use drugs (PWUDs) and 
non-PWUDs hospitalized with influenza and, by controlling for those factors we find are 
significant, determine if there is an association between severe influenza outcomes and drug use. 
This analysis uses national FluSurv-NET data from the 2016-2017, 2017-2018, and 2018-
2019 influenza seasons on persons who were admitted to a hospital and had a laboratory-
confirmed positive test for influenza. Descriptive statistics, chi-square tests of independence, 
age-adjusted and crude odds/risk ratios, 95% confidence intervals, and logistic regression models 
were used to evaluate differences in demographics, risk and behavioral factors, specific drug use, 
and severe influenza outcomes among PWUD and non-PWUD cases. 
There were 51,265 lab-confirmed influenza hospitalizations, among whom were 1,766 
PWUDs. PWUDs were younger than non-PWUDs and more likely to be male, Black or Latinx, 
smoke tobacco, abuse alcohol, and have chronic conditions like asthma, chronic liver disease, 
chronic lung disease, or immunosuppressive conditions. PWUDs were more likely to experience 
ICU admission and mechanical ventilation but were not more likely to die during their 
hospitalization. PWUDs were less likely to receive the seasonal influenza vaccine, a protective 
intervention that was associated with decreased risk of ICU admission and being mechanically 
ventilated. These results have great potential to inform interventions with this at-risk population. 
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 Influenza is a perennial public health problem in the United States and around the world. 
Additionally, drug use, particularly regular or excessive drug use, is a significant and growing 
issue that is related to numerous health complications and conditions. Thus, there is reason to 
believe that drug use could be a significant modifying factor in influenza severity and in the risk 
for experiencing negative health outcomes due to influenza infection.  
The objectives of this investigation are to 1) compare the prevalence of demographic and 
behavioral factors associated with severe influenza outcomes between persons who use drugs 
(PWUDs) and non-PWUDS hospitalized with influenza, and 2) by controlling for those factors 
we find are significantly associated with PWUD status, determine whether there is a significant 
relationship between severe influenza outcomes and drug use. 
We hypothesized that PWUDs would have significant demographic differences and 
distinct behavioral risk factors such as differential smoke tobacco and/or alcohol use patterns and 
a higher prevalence of certain underlying conditions that could be related to drug use compared 
with non-PWUDs. We also anticipated that we would find a positive association between drug 
use and severe influenza outcomes including death, ICU admission, mechanical ventilation, 









The annual influenza epidemic causes significant morbidity and mortality in the United 
States and globally. In the 2018-2019 influenza season in the United States, an estimated  35.5 
million people had symptomatic infections, 490,561 people were hospitalized, and 34,157 people 
died (CDC, 2020). Because the actual magnitude of each influenza season has been difficult to 
quantify, modeling based on surveillance data has been used to determine influenza severity and 
predict outcomes. Identifying new factors affecting influenza spread and/or severity could result 
in modifications to make the models more accurate (Schulte & Hser, 2013).  
Drug use is associated with myriad health complications and diseases throughout the 
lifespan (Simonsen, Fukuda, Schonberger, & Cox, 2000), and use and abuse of drugs as well as 
overdose deaths have increased nationwide since 2000 (NIDA, 2015; Rudd, Aleshire, Zibbell, & 
Matthew Gladden, 2016). Several studies have found that opioids, including prescription opioids, 
can impair respiration and lung function, reduce the effectiveness of the immune system, and 
lead to adverse effects such as slowed breathing and lung-damaging inflammation and bullae 
formation (McCain, Werlang, Khoor, & Mira-Avendano, 2018; Yamanaka & Sadikot, 2013). 
Chronic heavy alcohol use has been shown to negatively impact the functioning of the immune 
system, while moderate alcohol use might in fact improve the ability of the immune system to 
fight infection (Barr, Helms, Grant, & Messaoudi, 2016; Roman, 2014). Inhaling drugs such as 
marijuana, methamphetamine, and crack/cocaine can lead to lung damage and a variety of 
chronic lung conditions (Mégarbane & Chevillard, 2013; Nguyen, Silva, Souza, & Müller, 2007; 
Tseng, Sutter, & Albertson, 2014). Intravenous (IV) drug use has also been associated with lung 
disease (Karpel, 2019). However, little is known specifically about the impact of frequently used 
drugs on severe influenza outcomes. Studies have also shown a significant association between 
8 
 
heavy alcohol use and severe influenza outcomes: one study found, among all ages but especially 
in those 65 and older, heavy alcohol use was a risk factor for severe influenza outcomes such as 
ICU admission and death (Greenbaum et al., 2014). Other studies have connected chronic 
alcohol consumption to decreases in immune system efficiency and thus an increased risk for 
high-severity influenza infections (CDC, 2019a). Tobacco smoking has also been found to 
increase the risk of respiratory infection, influenza severity, and the likelihood of being admitted 
to the ICU due to influenza infection (Godoy et al., 2016; Han et al., 2019; Huttunen, Heikkinen, 
& Syrjänen, 2011). Beyond this, the distribution and severity of influenza among PWUDs are 
not well understood. With the ongoing opioid epidemic in the United States, it is possible that 
there is an increase in severe influenza outcomes that are related to opioid and other drug use and 
abuse.  
The Centers for Disease Control and Prevention (CDC) fund Emerging Infections 
Program (EIP) sites in 10 states nationwide with the goal of conducting disease surveillance, 
monitoring outbreaks, evaluating public health interventions, and using their findings to inform 
policy (Meyerholz et al., 2008). These states are California, Colorado, Connecticut, Georgia, 
Maryland, Minnesota, New Mexico, New York (which has two sites in Albany and Rochester), 
Oregon, and Tennessee; each site is connected with their State Department of Public Health 
while some are also connected to a prominent university health science center in the state. Each 
site conducts a variety of activities in different disease areas. One of these activities is the 
Influenza Hospitalization Surveillance Network (FluSurv-NET), which conducts population-
based surveillance for laboratory-confirmed, influenza-related hospitalizations to provide 
national estimates of influenza severity and vaccine effectiveness. FluSurv-NET sites are found 
at each of the EIPs and three additional states (Michigan, Ohio, and Utah) and represent 
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approximately 8.5% of the total population of the United States, or 27 million people (Meyerholz 
et al., 2008). Given this, the FluSurv-NET data are ideal for understanding the national 
distribution of and risk for severe influenza outcomes among PWUDs and determining if there is 
an association between severe influenza outcomes and drug use. 
Preliminary analyses of the potential association between severe influenza outcomes and 
drug use was done with Connecticut Flu-Surv-NET data. While findings were limited, they were 
intriguing enough to encourage a broader analysis of all-site data. For example, the Connecticut 
Flu-Surv-NET data showed that persons who use drugs including opioids were younger, were 
more likely to be male, and were more likely to require mechanical ventilation, a severe 
influenza complication. They were also more likely to have at least one mental health condition 
and were less likely to be vaccinated against influenza before their hospitalization; vaccination 
remains the best way to prevent influenza infection and severe outcomes (CDC, 2019b; Uyeki et 
al., 2018). A recommendation from this preliminary analysis was that drug use treatment, syringe 
exchange programs, emergency departments, and mental health treatment facilities might be 
impactful target sites for vaccination interventions. A more detailed analysis looking at all 
FluSurv-NET site data from 2016 to 2019 with a focus on severe influenza outcomes and drug 






FluSurv-NET Data Collection 
FluSurv-NET tracks community-acquired, laboratory-confirmed, influenza-related 
hospitalizations. These are defined as an admission to one of the catchment area hospitals that is 
fourteen or fewer days after or less than three days before a positive influenza test result between 
October 1–April 30 each year (Chaves, Lynfield, Lindegren, Bresee, & Finelli, 2015). The time 
interval criteria lessen the possibility that nosocomial cases will be included. The case must also 
live in the catchment area monitored by the FluSurv-NET site and be hospitalized for at least 24 
hours. Influenza hospitalizations are reported weekly to the CDC Influenza Division by the 
FluSurv-NET sites, along with key variables (hospital admission date, patient date of birth, type 
of influenza test and influenza type). The median lag time for this initial reporting is 7 days, and 
allows the CDC to report incidence and prevalence of influenza in almost real-time (Chaves et 
al., 2015). Additional information on over 400 variables of interest including demographic and 
location data, risk and behavioral factors, and significant health outcomes are collected via 
retrospective medical record reviews and patient/provider interviews. These data are reported to 
the CDC by the sites before the end of the year, after the data have been cleaned.   
During the 2017-2018 season, FluSurv-NET implemented an optional sampling strategy 
and a new Case Report Form (CRF) to accommodate the record number of hospitalized cases. 
Until that season, all sites collected complete data on the nearly 400 variables for each identified 
case on a standard CRF. However, from the 2017-2018 season on, sites had the option to 
continue doing complete chart reviews or begin implementing sampling strategies. Sampling 
strategies involve identifying all lab-confirmed influenza-associated hospitalizations in the 
catchment areas; conducting a full chart review for all children, adults under 50 years old, and 
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those who died; sampling a proportion of older adult cases for complete review; and conducting 
a partial review for non-sampled cases that includes only key variables of interest (hospital 
admission date, patient date of birth, type of influenza test and influenza type). In the 2017-2018 
season, one site (Minnesota) sampled among cases over 65 years old and six additional sites 
(California, Georgia, New Mexico, New York: Albany, Ohio, and Oregon) sampled among cases 
50-64 and 65+ years old. In the 2018-2019 season, six sites (California, Georgia, New Mexico, 
New York: Albany, Ohio, and Oregon) sampled among cases 65 years and older. This was 
accounted for in the analysis through weighting by sampling strategy and state. 
Drug use was defined as evidence in the medical record of current use, dependence, or 
hazardous use of any drugs in the previous 12 months and was recorded as “substance abuse” in 
the dataset provided by the CDC. For this analysis, a case’s drug use status was determined by 
any record of substance abuse, IV drug use, or opioid abuse in the medical chart. Drugs recorded 
were primarily illicit drugs that were illegal to use in all the states where FluSurv-NET sites were 
located. Tobacco use, alcohol abuse, marijuana use, and e-cigarette use were all recorded as 
behavioral risk factors instead of substance abuse factors because of differential state laws and 
regulations. Data on marijuana and e-cigarette use were only recorded in the 2017-2018 and 
2018-2019 seasons. Data on specific drug class was only reported in the 2017-2018 and 2018-
2019 seasons; therefore, any analysis of these variables did not include cases from the 2016-2017 
season. Drug classes included were (Drug Enforcement Administration, 2017): 
1. Depressants such as benzodiazepines and barbiturates; 
2. Stimulants which included amphetamines and cocaine;  
3. Opioids, primarily prescription drugs and heroin; 
4. Hallucinogens such as mushrooms, PCP, and “club drugs” like MDMA; 
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5. Inhalants (but not e-cigarettes), which ranged in type. 
There were also some substances that were difficult to define or were not available in the 
medical record. These were recorded as “unspecified.” 
Data Analysis 
Descriptive statistics, chi-square tests of independence, odds ratios, and 95% confidence 
intervals were used to evaluate differences in demographics, risk and behavioral factors, specific 
drug use, and severe influenza outcomes among PWUDs and non-PWUDs. A Cochran–Mantel–
Haenszel analysis was conducted to control for age among severe influenza outcomes between 
PWUDs and non-PWUDs. Logistic regression models, weighted with methods recommended by 
the CDC to accommodate the sampling done in the 2017-2018 and 2018-2019 seasons, were 
developed to examine drug use and other variables that were significantly predictive for 
vaccination, antiviral treatment, and severe outcomes among hospitalized influenza cases. 
Models were formed by initially including all statistically significant variables (p<0.05), then 
using backwards elimination until only those that remained significant were included. If not 
significant, drug use was forced into the final model to assess the strength and direction of the 
residual relationship to the outcome.  
There were 51,265 lab-confirmed influenza hospitalizations identified within the 
FluSurv-NET catchment areas between the 2016-2017, 2017-2018, and 2018-2019 seasons, 
which provided sufficient power to address the aims of the study. The CDC estimates that there 
were 500,000 hospitalizations in the 2016-2017 season, 810,000 in 2017-2018, and 490,561 in 
2018-2019 (CDC, 2020). 
All analyses were conducted using SAS version 9.4 and Epi Info from the CDC website. 






 In the overall sample, cases were about evenly distributed among the three seasons with a 
slightly greater percentage of cases in the 2017-2018 season (37.4%; see Table 1a). The states 
with the most cases represented in the sample were, in order, Maryland (12.6% of cases), New 
York (11.5%), Colorado (11.0%), and California (10.7%), with New Mexico (1.7%) representing 
the fewest percentage of cases. The sample was majority female (54.4%) and White (58.7%), and 
the median age was 65 years old. 
 Most of the sample had at least one medical condition (87.8%) (Table 1b). Less than half 
of the sample (46.8%) were known to have received their seasonal influenza vaccine prior to 
being hospitalized. The most reported medical conditions were chronic cardiovascular disease 
(44.1%), chronic metabolic disease (39.2%), and chronic lung disease (27.0%). Nearly 19% of 
the sample were current tobacco smokers, and 3.1% reported current alcohol abuse. 
 Most of the cases survived their hospitalization (96.5%; 3.2% were known to have died, 
see Table 1c). The median length of stay (LOS) was 3 days. The distribution of influenza 
subtypes was majority influenza A (81.4%) then influenza B (18.0%). Approximately 16% of 
cases went to the ICU and 5.7% were mechanically ventilated. Approximately 22% were 
diagnosed with pneumonia, 16.4% with sepsis, and 1.3% with bacteremia. Overall, 62.8% of 





Prevalence of Drug Use and Frequency of Missing Data by Demographic Characteristics, Risk 
Factors, and Outcomes  
There were 1,766 cases (3.4% of the overall sample) with reported drug use over the 
three seasons of interest. PWUDs had a lower median age than non-PWUDs (53 years vs 66 
years; see Table 2a). Eight percent (8%) of people between 18-49 years old and 7.4% of people 
between 50-64 years old were PWUDs. Approximately 4% of males were PWUDs compared 
with 2.7% of females. The number of PWUD cases and proportion of PWUDs in the sample 
increased with each season (499 cases in 2016-2017, 3.1% of all 2016-2017 cases; 631 cases in 
2017-2018, 3.3% of all 2017-2018 cases; 636 cases in 2018-2019, 3.9% of all 2018-2019 cases). 
Among all cases from Oregon, 5.6% were PWUDs which was the highest prevalence of any 
state, and it was followed by New Mexico at 5.2% and Maryland, Utah, and California all at 
4.9%. Figure 1 shows the prevalence of PWUDs among persons hospitalized with influenza in 
each state. There was very little missing demographic data among either PWUDs or non-
PWUDs. 
Approximately 7% of people who identified as Black and 4% of people who identified as 
Latinx were PWUDs compared with 3% of Whites (see Table 2b). Twenty-two percent (22%) of 
people who currently abuse alcohol were PWUDs, and 12.8% of current tobacco smokers were 
PWUDs. Only 2.1% of people who received their seasonal influenza vaccine were PWUDs. 
While there was no immediately discernable differences between the percentages of PWUD and 
non-PWUD cases with preexisting medical conditions, as body mass index (BMI) decreased the 
percentage in each group that were PWUDs increased. Among risk factors, there were some 
notable percentages and differences in missing data. Non-PWUDs had approximately 30% more 
missing data than PWUDS, but for most variables, missing data were less than 2% of the total. 
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However, it was more than 10% for BMI and approximately 30% for chronic lung disease and 
pregnancy status.  
Approximately 5% of ICU admissions were PWUDs, as well as 6% of mechanical 
ventilation cases, 4% of pneumonia cases, and 7% of bacteremia cases (see Table 2c) The 
percentage of missing data for all outcomes was less than 3%. As for other factors, missing data 
were more common among non-PWUDs than PWUDs. 
For all the above factors and outcomes, further analysis was needed to determine if these 
differences were significant and what other factors could be associated with these outcomes. 
Specific Drug Use 
Data on specific drug use was only collected in the 2017-2018 and 2018-2019 seasons. 
Thus, the analysis of specific drug use was limited to 1,267 adult PWUDs and 34,017 adult non-
PWUDs from those seasons. Among PWUDs, stimulants including amphetamine, 
methamphetamine, and crack/cocaine, was the most widely used class of drug with 56% of 
PWUDs indicating use (see Figure 2). Opioids including prescription drugs, fentanyl, and heroin 
was the next most widely used drug class with 39% of all PWUDs indicating use. Depressants 
including benzodiazepines and barbiturates (4%) and hallucinogens including MDMA, PCP, and 
mushrooms (1%) were the next most widely used drug classes, with inhalants and unspecified 
drug class combined making up less than 0.3% of all drug use.  
Not shown in Figure 2 are the substances that were recorded as behavioral risk factors: 
smoke tobacco use, e-cigarette use, alcohol at the level of abuse, and marijuana. Marijuana and 
e-cigarette use were also only recorded in the 2017-2018 and 2018-2019 seasons while alcohol 
abuse and smoke tobacco use were recorded in all three seasons. These analyses were done on 
adults only—pediatric cases under 18 were excluded from the analysis—and can be found in 
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Table 3b for tobacco and alcohol abuse and Table 4 for marijuana and e-cigarette use. Compared 
with the never/unknown group, PWUDs were significantly more likely than non-PWUDs to 
currently smoke tobacco (OR: 11.59, 95% CI: 10.15-13.24, p<0.001) and currently abuse alcohol 
(OR: 9.59, 95% CI: 8.43-10.92, p<0.001). PWUDs also were significantly more likely than non-
PWUDs to use marijuana (OR: 9.11, 95% CI: 7.94-10.45, p<0.001) and e-cigarettes (OR: 2.94, 
95% CI: 1.41-6.14, p=0.003). 
Breaking down specific drug use by site, hallucinogen use was most prevalent in 
Connecticut with 3.4% of PWUDs reporting use and 7 FluSurv-NET sites reporting no use (see 
Figure 3). Stimulant use was most prevalent in Georgia with 57.7% of PWUDs reporting use 
while only 13.9% of PWUDs reported use in Michigan; cocaine/crack was the most commonly 
reported type of stimulant at most sites but not at the New Mexico, Utah, Oregon, or Colorado 
sites (see Figure 4). Opioid use was most prevalent in New Mexico with 45.7% of PWUDs 
reporting use and least prevalent in Georgia with only 10.6% of PWUDs reporting use; heroin 
was not the most commonly used type of opioid at any site, but at the Connecticut site 10.6% of 
all PWUDs reported heroin use, the greatest prevalence of heroin use (see Figure 5). Depressant 
use was most prevalent at the New York: Albany site with 9.1% of PWUDs reporting use and 
least prevalent at the Tennessee, Michigan, and New York: Rochester sites with no PWUDs 
reporting use (see Figure 6). 
Comparison of PWUDs and Non-PWUDs 
For these analyses, children under 18 were excluded as they had a low prevalence of 
PWUD status and adult PWUDs were of greater interest, as they have different underlying 
conditions than children and recommended interventions will likely be more appropriate for 
adults. This new sample thus had 1,759 PWUDs and 44,181 non-PWUDs. Additionally, the 18-
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49- and 50-64-year-old groups were combined to simplify the analysis, as they were not 
statistically different from each other in prevalence of drug use. 
When looking at the odds/risk ratios and p values for significance at the p=0.05 level, 
associations between PWUD status, demographics, risk factors, and outcomes become more 
apparent. Compared with the baseline 2016-2017 season, PWUDs were more likely to be from 
the 2018-2019 season (OR: 1.35, 95% CI: 1.20-1.52, p<0.001; see Table 3a). Compared with the 
reference 18-64 year old group, PWUD cases were significantly less likely to be in any other age 
group. The majority (57%) of PWUDs were male and being female had a significant protective 
effect against PWUD status (OR: 0.57, 95% CI: 0.52-0.63, p<0.001). Compared with the White 
group, PWUDs were more likely to be Black (OR: 3.04, 95% CI: 2.74-3.37, p<0.001) or Latinx 
(OR: 1.79, 95% CI: 1.50-2.15, p<0.001) but less likely to be Asian/Pacific Islander (OR: 0.28, 
95% CI:0.17-0.46, p<0.001). 
PWUDs were significantly more likely to have asthma (OR: 1.48, 95% CI: 1.33-1.65, 
p<0.001; see Table 3b), chronic liver disease (OR: 7.52, 95% CI: 6.65-8.51, p<0.001), chronic 
lung disease (OR: 1.32, 95% CI: 1.20-1.46, p<0.001), or an immunosuppressive condition (OR: 
1.19, 95% CI: 1.06-1.34, p<0.001) and significantly less likely to receive their seasonal influenza 
vaccine prior to their hospitalization (OR: 0.43, 95% CI: 0.39-0.48, p<0.001). 
PWUDs were not significantly more likely to die during their hospitalization (RR: 0.81, 
95% CI: 0.61-1.07, p=0.129; see Table 3c). However, they were significantly more likely to have 
a hospital admission longer than two weeks (RR: 1.52, 95% CI: 1.29-1.79, p<0.001), to stay in 
the ICU (RR: 1.44, 95% CI: 1.32-1.57, p<0.001), be mechanically ventilated (RR: 1.71, 95% CI: 
1.47-1.98, p<0.001), and experience sepsis (RR: 1.23, 95% CI: 1.13-1.35, p<0.001), pneumonia 
(RR: 1.24, 95% CI: 1.15-1.34, p<0.001), and bacteremia (RR: 2.03, 95% CI: 1.52-2.73, 
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p<0.001). They were not significantly more or less likely to receive antiviral treatment (OR: 
1.08, 95% CI: 0.98-1.19, p=0.132).  
Age-Adjusted Analysis 
Given that PWUDs were a significantly younger population that experienced many 
severe outcomes at a significantly higher prevalence, an age-controlled analysis of outcomes, 
continuing to exclude children under 18 years old, was completed using a Cochran–Mantel–
Haenszel Stratified Analysis to determine age-controlled odds/risk ratios. These would provide 
insight into the potentially confounding effect of age and help inform the creation of the logistic 
regression model. After this analysis, it was apparent that age was a confounding variable as all 
the odds/risk ratios for outcomes of interest were changed between the crude and controlled 
values (see Table 5). The most dramatic example of this was the outcome of death, where 
PWUD status trended towards being protective in the crude analysis but was not significant 
(RR=0.81, 95% CI: 0.62-1.07), while in the age-controlled analysis it was a significant risk 
factor for death (Adjusted RR: 1.33, 95% CI:1.00-1.77, p=0.049). PWUD status was still 
associated with lesser odds of receiving an influenza vaccine (Adjusted OR: 0.70, 95% CI: 0.62-
0.78, p<0.001) and greater risk of being admitted to the ICU (Adjusted RR: 1.29, 95% CI: 1.19-
1.42, p<0.001) and being mechanically ventilated (Adjusted RR: 1.45, 95% CI: 1.25-1.69, 
p<0.001). There was no significant difference in the odds of receiving antiviral treatment 
between PWUDs and non-PWUDs before and after controlling for age.  
Factors Associated with PWUD Status: Logistic Regression Model Results 
 After adjusting for non-significant variables at the p=0.05 level and removing missing 
data, there were 24,615 observations over the three seasons for the logistic regression analysis. 
Variables of interest that showed significance in previous analyses were included and were: 
19 
 
season, age (excluding children under 18 years old), race/ethnicity, sex, PWUD status, smoke 
tobacco use, alcohol abuse, vaccination status, overall preexisting medical conditions and 
specific conditions like asthma, chronic liver disease, chronic lung disease, and 
immunosuppressive conditions, ICU admission, mechanical ventilation, pneumonia, sepsis, 
bacteremia, antiviral treatment, and death. Reference groups were, where applicable, the lack of 
the health condition, treatment, or outcome. Otherwise, the reference groups were the 2016-2017 
influenza season, White race, the 18-64 year old age group, and male sex. 
The final model for death showed that older age, asthma, chronic liver disease, and 
immunosuppressive conditions were significantly associated with greater odds of death. PWUD 
status was not associated with death. Antiviral treatment was significantly protective against 
death (OR: 0.58, 95% CI: 0.42-0.80, p=0.001; see Table 6a.i). Another model for death, 
including only age, drug use, vaccination, and antiviral treatment was created to see if underlying 
conditions associated with drug use, rather than drug use itself, could provide an explanation for 
finding no association between death and PWUD status in this model despite it being evident in 
the age-adjusted model (see Table 6a.ii). In this model, age and receiving antiviral treatment 
remained significant and retained their original risk associations with death from the first model. 
Drug use trended towards being a risk factor for death when compared with the first model (OR: 
1.16, 95% CI: 0.75-1.80, p=0.513 vs. OR: 0.91, 95% CI: 0.58-1.43, p=0.691 in the first model) 
but was still not significant. There was no significant predictive association between vaccination 
and death. 
Older age, female sex, and Black race were protective against ICU admission. Being 
Asian/Pacific Islander and having chronic lung disease or asthma were significantly associated 
with greater odds of ICU admission (see Table 6b). PWUD status was positively associated with 
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ICU admission and this was significant at the p=0.05 level (OR: 1.26, 95% CI: 1.06-1.49, 
p=0.008). Receiving the seasonal influenza vaccine was protective against being admitted to the 
ICU (OR: 0.89, 95% CI: 0.82-0.97, p=0.006). Antiviral treatment was not significantly 
associated with ICU admission. 
Variables associated with mechanical ventilation included PWUD status (OR: 1.66, 95% 
CI: 1.31-2.10, p<0.001; see Table 6c) and having chronic lung disease (OR: 1.61, 95% CI: 1.42-
1.82, p<0.001) or asthma (OR: 1.003, 95% CI: 1.002-1.005, p<0.001). Receiving the seasonal 
influenza vaccine was protective against mechanical ventilation (OR: 0.66, 95% CI: 0.58-0.74, 
p<0.001). Antiviral treatment was not significantly associated with mechanical ventilation. 
Having received the seasonal influenza vaccine prior to hospitalization was associated 
with older age, former smoke tobacco use, former alcohol abuse, having chronic liver disease, 
chronic lung disease, or an immunosuppressive condition. Groups less likely to receive the 
vaccine were those who identified as Black (OR: 0.62, 95% CI: 0.58-0.67, p<0.001; see Table 
6d) or Latinx (OR: 0.71, 95% CI: 0.63-0.80, p<0.001), were PWUDs (OR: 0.81, 95% CI: 0.69-
0.95, p=0.008), had current smoke tobacco use or alcohol abuse, and those with asthma.  
Receiving antiviral treatment was significantly less likely to happen in the 2017-2018 
(OR: 0.034, 95% CI: 0.026-0.045, p<0.001; see Table 6e) season and much more likely to 
happen in the 2018-2019 season (OR: 2.56, 95% CI: 1.94-3.37, p<0.001). This was the only 






 Results from this analysis address a significant gap in the existing literature on the 
relationship between drug use and severe influenza outcomes. Severe outcomes due to influenza-
related complications that were of interest in this study included pneumonia, sepsis, bacteremia, 
ICU admission, mechanical ventilation, and death, although hospitalization due to influenza-
related complications is a severe outcome in itself and was a requirement for inclusion in the 
study. We were also interested in evidence related to the efficacy of the seasonal influenza 
vaccine and antiviral treatment.  
We found that, compared with non-PWUDs, PWUDs were younger, were more likely to 
be male, had more behavioral risk factors including alcohol abuse and smoke tobacco use, and 
had differential prevalence of specific comorbid conditions including asthma, chronic lung 
disease, immunosuppressive conditions, and chronic liver disease. These underlying conditions 
that were more common among PWUDs were expected based on the literature (McCain et al., 
2018; Mégarbane & Chevillard, 2013; Nguyen et al., 2007; Roman, 2014; Tseng et al., 2014; 
Yamanaka & Sadikot, 2013), but this study also found that they were mitigating factors in the 
analysis of the death outcome for PWUDs. Each of these underlying conditions had an 
independent association with death and controlling for age resulted in an association between 
PWUD status and death that disappeared when these underlying conditions were added. 
Smoking and alcohol abuse have been found to be associated with negative health outcomes due 
to lung infection and influenza in past studies (Greenbaum et al., 2014; Huttunen et al., 2011); 
PWUDs had a higher prevalence of use for both, but they were not found to be independent risk 
factors for negative outcomes in the logistic regression models. PWUDs were also less likely to 
receive their seasonal influenza vaccination prior to their hospitalization. This mixture of 
22 
 
protective (younger age) and risk factors (underlying conditions, lower vaccination rates) made 
the relationship between any of the health outcomes examined and PWUD status uncertain 
unless we controlled for both types of factors.  
PWUD status increased in prevalence as the seasons progressed. This could be attributed 
at least in part to the FluSurv-NET CRF being modified each season to have more areas for 
details about drug use to be recorded. Moreover, drug use received more national attention due to 
the opioid epidemic which reached a peak in 2016 (HHS, 2019). It is possible that overall drug 
use increased even if opioid use nationally peaked in 2016, but we do not know for certain why 
PWUD status increased each year in this analysis. Additional analyses could look at different 
classes of drugs by year to determine if use increased for opioid and non-opioid drug classes.  
PWUDs hospitalized for influenza had a greater risk of ICU admission, mechanical 
ventilation, pneumonia, sepsis, and bacteremia. Drug use has been found to be associated with 
negative outcomes like pneumonia (Olubamwo et al., 2018) that also can be direct consequences 
of influenza infection (Morens, Taubenberger, & Fauci, 2008) as well as conditions like 
bacteremia and sepsis that are indirect consequences of influenza infection (Florescu & Kalil, 
2014; Morris, Cleary, & Clarke, 2017), so these results were expected. While pneumonia, sepsis, 
and bacteremia could result in ICU admission and mechanical ventilation, they could also be 
nosocomial infections resulting from ICU admission and mechanical ventilation. For this 
analysis the data on timing of these events was unavailable, so it is unknown whether 
pneumonia, bacteremia, and/or sepsis occurred before admission to the ICU or before being 
mechanically ventilated. 
When controlling for the potentially confounding effect of age due to the differential age 
distribution of PWUDs and non-PWUDs, all the odds/risk ratios for outcomes and risk factors of 
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interest (death, ICU admission, mechanical ventilation, antiviral treatment, and vaccination) 
changed between the crude and adjusted values, indicating that age was a confounding factor in 
this analysis. However, death was the only outcome where the effect of the relationship reversed 
and gained significance.  
In the predictive logistic regression models, older age, asthma, chronic liver disease, 
chronic lung disease, and immunosuppressive conditions were associated with a greater risk for 
death, while antiviral use was protective. Drug use was not significantly associated with death. 
To determine if underlying health conditions related to drug use, rather than drug use itself, 
could better explain the relationship between death and PWUD status, a second model without 
underlying conditions was created and found that, while increased age remained significantly 
positively associated with death and antiviral treatment remained significantly protective against 
death, drug use trended towards being a risk factor for death though it still was not significant. 
Additionally, there was no significant association between influenza vaccination and death. 
Thus, the age-adjusted association of drug use with increased risk of death appears to be 
mediated by having underlying, drug-associated conditions rather than a direct consequence of 
drug use itself.  
Controlling for demographic factors, underlying conditions, and vaccination status, drug 
use was a risk factor for ICU admission and mechanical ventilation.  The mechanism for these 
associations is unclear, but to our knowledge this is the first time that PWUD status has been 
found to be associated with ICU admission and mechanical ventilation among persons 
hospitalized with influenza independently of underlying conditions associated with drug use. 
Vaccination was protective against both ICU admission and mechanical ventilation. 
Vaccination was not found to be significantly protective against death in this analysis. Why 
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vaccination was not protective against death in this analysis is unknown, since it is regarded as 
the best way to prevent influenza infection and death in the literature and in practice (Dawood et 
al., 2020; Uyeki et al., 2018). The low number of deaths, the limited number of seasons, and the 
low effectiveness of the vaccines used during those seasons may have minimized the chance to 
find a difference. Each season had a vaccine effectiveness against infection that was lower than 
40%, and the 2018-2019 season’s vaccine effectiveness was notoriously low with an estimated 
effectiveness of just 29% against infection (Flannery et al., 2018; Flannery et al., 2019; Rolfes et 
al., 2019). The relatively low ability of the vaccine to prevent severe influenza outcomes during 
the study time period may be different in other time periods when vaccine effectiveness against 
infection is higher. Similar analyses during different influenza seasons are needed to confirm or 
refute these results.  
Older age was a predictor for vaccination, supporting previous findings and the goals of 
most influenza vaccination efforts that target older adults (CDC, 2013; Rolfes et al., 2019; 
Smetana, Chlibek, Shaw, Splino, & Prymula, 2018). PWUDs being significantly younger than 
non-PWUDs could contribute to PWUDs being less likely to receive their influenza vaccine. 
Being Black or Latinx was associated with lower odds of receiving the influenza vaccine while 
being Asian/Pacific Islander was associated with greater odds of receiving the influenza vaccine. 
This adds to the literature surrounding race/ethnicity and vaccination (Lu, Qiao, Brown, & 
Wang, 2017; Tse, Wyatt, Trinh-Shevrin, & Kwon, 2018).  
Consistent with the literature, antivirals were protective of some severe influenza 
outcomes including death (Domínguez et al., 2018; Wang et al., 2015). The only variable that 
was significantly associated with receiving antiviral treatment was season; compared with the 
2016-2017 season, antiviral use was less likely in the 2017-2018 season and more likely in the 
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2018-2019 season. This could reflect differential prescribing practices between the three years or 
the introduction of a new antiviral influenza treatment, Baloxavir marboxil, in 2018 (CDC, 
2019c).  
Influenza vaccination is one of the most effective ways to prevent influenza infection 
(Uyeki et al., 2018), and this analysis found that vaccination was significantly protective against 
ICU admission and mechanical ventilation, severe outcomes of influenza. Antiviral treatment 
was associated with a reduced risk for death and is recommended to control outbreaks as both a 
treatment and a form of preexposure/postexposure prevention (Uyeki et al., 2018). This provides 
further evidence for influenza vaccination and antiviral treatment campaigns being potentially 
powerful targets for intervention and prevention, particularly among the population of PWUDs 
(CDC, 2019b). 
Limitations 
 There are several important limitations to consider in the interpretation of the data. First, 
because of varying FluSurv-NET site population differences, state laws concerning drug use, and 
hospital and lab testing practices (some hospitals test all admissions while others do not, some 
use more sensitive tests, etc.), between-site differences in PWUD status and other demographic 
and risk factors are expected. Differential sampling strategies between the sites were accounted 
for through weighting during the analysis. However, varying state effects could have led to an 
unrepresentative sample during data collection and could influence findings in unknown ways.  
Second, as evidenced with the sampling method changes between the three influenza 
seasons, events beyond the control of public health professionals such as a bigger, more severe 
seasonal epidemic than expected can change surveillance practices by year. Hopefully this was 
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adequately accounted for in the weighted analysis that was recommended by the CDC, but there 
is the chance that the sampling that was done led to an unrepresentative sample. 
 Third, drug use is a self-reported variable as elicited by the hospital healthcare providers. 
Thus, the true prevalence of drug use could be underrepresented if people do not want to disclose 
their status to their doctors due to fears of punishment or stigma or if the hospital the case 
presented to does not regularly screen incoming patients. Additionally, the drug type could 
potentially be reported incorrectly if there was a miscommunication between the patient and 
doctor, the doctor did not ask about all classes of drugs, or the patient did not fully disclose all 
substances used. For this analysis, all drug classes and modes of taking them (e.g., IV, inhaling, 
ingesting, etc.) were lumped together, which might have minimized the effect of any one drug 
class if their effects are influenced by the method of use. Future analyses should examine each 
major drug classes and mode of administration separately. 
Finally, this study was not designed to look at the relative risk of hospital admission in 
PWUDs vs non-PWUDs; as such, it can only examine those factors relating to other severe 
outcomes among those hospitalized. This study cannot determine if demographics or factors like 
drug use, smoke tobacco use, alcohol abuse, or underlying conditions are risk factors for hospital 
admission due to influenza infection. By many standards, a hospital admission due to influenza 
infection is a severe outcome in itself, so the entire population we are looking at in this study has 
already experienced a severe negative health outcome due to their influenza infection even if 
they did not experience the extreme negative outcomes that were focused on in this study. To 
determine the association between drug use and hospital admission due to influenza infection, a 
new analysis comparing influenza hospital admissions with influenza cases who were not 
admitted  would be necessary.  
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Recommendations and Conclusions 
 Further investigation is warranted to confirm these results. In future analyses, it will be 
important to analyze the effects of specific drug types and modes of administration on severe 
influenza outcomes to determine if there are differential associations. In addition, given the 
potential for differences between each of the sites, a site-by-site analysis could determine the 
extent and scale of variation between the sites and also pinpoint unique concerns such as a 
greater prevalence of a certain drug class that leads to severe health outcomes at a specific site. 
This could inform interventions by area that can be tailored to a site’s needs and therefore be 
more effective.  
Lower socioeconomic status has been associated with poor health outcomes, a higher 
prevalence of drug use with its own poor health outcomes, higher prevalence of influenza, and 
lower influenza vaccination rates (Braveman, Cubbin, Egerter, Williams, & Pamuk, 2010; Galea 
& Vlahov, 2002; Hadler et al., 2016; Stone, Krueger, Steptoe, & Harter, 2010). An analysis that 
includes an SES variable such as census-tract poverty could confirm or refute the potentially 
confounding effect of socioeconomic status on the association between drug use and severe 
influenza outcomes and also provide important insight into the interaction of socioeconomic 
status and drug use on the prevalence of risk factors and outcomes.  
 More complete data on PWUD status and severe outcomes due to influenza infection will 
allow further description and understanding of the relationship between the two health 
conditions. Confirming if drug use is a population-level risk factor for hospitalization due to 
influenza infection, and not just for severe outcomes upon hospitalization, could contribute to 
evidence for drug use being a specific indicator for vaccination similar to living or working in an 
at-risk setting, being above 65 years old, being pregnant, or having certain health conditions 
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(CDC, 2018). Research has found that PWUDs do access the health care system, but more often 
for other conditions rather than for their drug use, so increased screening for drug use is critical 
to make sure patient records are accurate and to make sure PWUDs receive appropriate care for 
all of their conditions (Substance Abuse and Mental Health Services Administration & Office of 
the Surgeon General, 2016).  
Given that PWUDs are significantly less likely to receive their seasonal influenza 
vaccines, and the results of this study which indicate that vaccines and antiviral treatment are 
significantly protective against severe influenza outcomes, offering vaccination and making 
antiviral treatments more widely available at drug use treatment facilities, syringe exchange 
programs, and emergency departments might be an impactful strategy to improve vaccination 
and prevent severe disease outcomes. PWUDs are an already at-risk group for negative health, 
including more severe influenza infection once hospitalized, and these results can be used to 
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Tables 1a-c. Demographic Characteristics, Risk Factors, and Outcomes of Patients 
Hospitalized with Laboratory-Confirmed Influenza, FluSurv-NET, 2016-2017, 2017-2018, 
and 2018-2019 Seasons 
Table 1a. Demographic Characteristics 
  Total                                                              
  N = 51,265 % 
Influenza Season 
2016-2017  15,981 31.2 
2017-2018  19,159 37.4 
2018-2019  16,125 31.5 
State 
        California 5,480 10.7 
        Colorado 5,614 11.0 
        Connecticut 3,384 6.6 
        Georgia 4,335 8.5 
        Maryland 6,438 12.6 
        Michigan 3,013 5.9 
        Minnesota 5,410 10.6 
        New Mexico 884 1.7 
        New York 5,863 11.5 
                Albany 1,876 3.7 
                Rochester 3,987 7.8 
        Ohio 2,782 5.4 
        Oregon 2,642 5.2 
        Tennessee 3,200 6.2 
        Utah 2,220 4.3 
Median Age (IQR) 65 (47-79) 
0-17y 5,325 10.4 
18-49y 8,514 16.6 
50-64y 11,501 22.4 
65-74y 8,929 17.4 
75-84y 8,940 17.4 
85y+ 8,056 15.7 
Sex 
Male 23,355 45.6 




White 30,065 58.7 
Black 10,704 20.9 
Latinx 4,164 8.1 
Asian/Pacific Islander 2,348 4.6 
American Indian or  
Alaska Native 
293 0.6 
Multiracial 155 0.3 
Unknown Race/Ethnicity 3,502 6.8 





Table 1b. Risk Factors 
  Total                                                              
  N = 51,265 % 
Smoke Tobacco Use 
Current 9,564 18.7 
Former 14,174 27.7 
Never/Unknown 27,387 53.4 
Missing Data 140 0.3 
Alcohol Abuse 
        Current 1,609 3.1 
        Former 1,299 2.5 
        Never/Unknown 48,216 94.1 
        Missing Data 141 0.3 
Substance Abuse 
       Current 1,706 3.3 
       Former 900 1.8 
       Never/Unknown 47,755 93.2 
       Missing Data 904 1.8 
IV Drug Use 
       Current 356 0.7 
       Missing Data 50,909 99.3 
Received Influenza Vaccine Prior to Hospitalization 
       Received Seasonal Influenza Vaccine in Corresponding Year 23,970 46.8 
       Did Not Receive Seasonal Influenza Vaccine in Corresponding 
Year 
19,517 38.1 
       Unknown Vaccine Status 7,562 14.8 
       Missing Data 216 0.4 
BMI 
       Underweight (<18.5 kg/m2) 2,205 4.3 
       Normal (>18.5 to 24.9 kg/m2) 14,133 27.6 
       Overweight (>25.0 to 29.9 kg/m2) 12,305 24.0 
       Obesity (>30.0 to 39.9 kg/m2) 12,443 24.3 
       Extreme Obesity (>40 kg/m2) 4,527 8.8 
       Missing Data 5,652 11.0 
Any Medical Condition 
Yes 45,005 87.8 
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No 5,748 11.2 
Unknown 372 0.7 
        Missing Data 140 0.3 
Asthma   
        Yes 10,833 21.1 
        No/Unknown 39,533 77.1 
        Missing Data 899 1.8 
Blood Disorders/Hemoglobinopathy   
        Yes 1,486 2.9 
        No/Unknown 48,880 95.4 
        Missing Data 899 1.8 
Chronic Cardiovascular Disease   
        Yes 22,599 44.1 
        No/Unknown 27,767 54.2 
        Missing Data 899 1.8 
Chronic Liver Disease   
        Yes 2,209 4.3 
        No/Unknown 33,178 64.7 
        Missing Data 15,878 31.0 
Chronic Lung Disease   
        Yes 13,820 27.0 
        No/Unknown 36,546 71.3 
        Missing Data 899 1.8 
Chronic Metabolic Disease   
        Yes 20,112 39.2 
        No/Unknown 30,254 59.0 
        Missing Data 899 1.8 
Chronic Renal Disease   
        Yes 9,465 18.5 
        No/Unknown 40,901 79.8 
        Missing Data 899 1.8 
History of Guillain-Barré Syndrome   
        Yes 71 0.1 
        No/Unknown 50,294 98.1 
        Missing Data 900 1.8 
Immunosuppressive Condition   
        Yes 8,678 16.9 
        No/Unknown 41,688 81.3 
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        Missing Data 899 1.8 
Neurologic Disease   
        Yes 10,004 19.5 
        No/Unknown 40,362 78.7 
        Missing Data 899 1.8 
Neuromuscular Disorder   
        Yes 2,830 5.5 
        No/Unknown 47,536 92.7 
        Missing Data 899 1.8 
Pregnant (Among Women of Childbearing Age)* 
Yes 1,177 16.0 
No/Unknown 3,964 53.9 
Missing Data 2,215 30.1 




Table 1c. Hospitalization Outcomes 
  Total                                                              
  N = 51,265 % 
Outcome 
Alive 49,481 96.5 
Deceased 1,624 3.2 
Unknown 54 0.1 
Missing Data 106 0.2 
Influenza Subtype   
Influenza A  41,740 81.4 
Influenza B 9,242 18.0 
Influenza A&B 172 0.3 
Influenza A/B (not distinguished) 82 0.2 
Unknown Subtype 29 0.1 
Median LOS in Days (IQR) 3 (2-5) 
        1 day 7,930 15.5 
        2-3 days 20,839 40.7 
        4-5 days 10,377 20.2 
        6-7 days 5,062 9.9 
        8-14 days 5,006 9.8 
        More than 2 weeks 1,961 3.8 
        Missing Data 90 0.2 
ICU Admission   
Yes 8,428 16.4 
No 42,575 83.1 
Unknown 155 0.3 
Missing Data 107 0.2 
Mechanical Ventilation   
Yes 2,901 5.7 
        No 48,061 93.8 
        Unknown 159 0.3 
Missing Data 144 0.3 
Sepsis   
        Yes 8,411 16.4 
        No/Unknown 41,563 81.1 
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        Missing Data 1,291 2.5 
Pneumonia   
        Yes 11,075 21.6 
        No/Unknown 40,190 78.4 
Bacteremia   
        Yes 652 1.3 
        No/Unknown 49,320 96.2 
        Missing Data 1,293 2.5 
Received Antiviral Treatment During Hospitalization   
        Yes 32,193 62.8 
        No/Unknown 18,718 36.5 





Tables 2a-c. Prevalence of Drug Use (PWUDs) and Missing Data, Persons Hospitalized 
with Laboratory-Confirmed Influenza, FluSurv-NET, 2016-2017, 2017-2018, and 2018-
2019 Seasons 







of Missing Data 
(PWUD/nPWUD) 
p value 
 N % N % - - 
  1,766 3.4 49,499 96.6 - - 
Influenza Season       
2016-2017  499 3.1 15,482 96.9 
- - 2017-2018  631 3.3 18,528 96.7 
2018-2019  636 3.9 15,489 96.1 
State       
        California 267 4.9 5,213 95.1 
- - 
        Colorado 195 3.5 5,419 96.5 
        Connecticut 116 3.4 3,268 96.6 
        Georgia 104 2.4 4,231 97.6 
        Maryland 315 4.9 6,123 95.1 
        Michigan 36 1.2 2,977 98.8 
        Minnesota 138 2.6 5,272 97.4 
        New Mexico 46 5.2 838 94.8 
        New York 142 2.4 5,721 97.6 
                Albany 33 1.8 1,843 98.2 
                Rochester 109 2.7 3,878 97.3 
        Ohio 84 3.0 2,698 97.0 
        Oregon 147 5.6 2,495 94.4 
        Tennessee 67 2.1 3,133 97.9 
        Utah 109 4.9 2,111 95.1 
Median Age (IQR) 53 (42-60) 66 (48-80)  
0-17y 7 0.1 5,318 99.9 
- - 
18-49y 680 8.0 7,834 92.0 
50-64y 855 7.4 10,646 92.6 
65-74y 182 2.0 8,747 98.0 
75-84y 32 0.4 8,908 99.6 
85y+ 10 0.1 8,046 99.9 
Sex   
        Male 1,017 4.4 22,338 95.6 
- - 
Female 749 2.7 27,161 97.3 
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Race/Ethnicity   
       White 781 2.6 29,284 97.4 
0 0.27 
Black 719 6.7 9,985 93.3 
Latinx 149 3.6 4,015 96.4 
Asian/Pacific Islander 17 0.7 2,331 99.3 
American Indian or  
Alaska Native 
12 4.1 281 95.9 
        Multiracial 6 3.9 149 96.1 
        Unknown Race/Ethnicity 82 2.3 3,420 97.7 












of Missing Data 
(PWUD/nPWUD) 
p value 
 N % N % - - 
  1,766 3.4 49,499 96.6 - - 
Smoke Tobacco Use 
Current 1,222 12.8 8,342 87.2 
0 0.025 
Former 262 1.8 13,912 98.2 
Never/Unknown 282 1.0 27,105 99.0 
Missing Data 0 0.0 140 100.0 
Alcohol Abuse 
        Current 366 22.7 1,243 77.3 
0 0.025 
        Former 120 9.2 1,179 90.8 
        Never/Unknown 1,280 2.7 46,936 97.3 
        Missing Data 0 0.0 141 100.0 




508 2.1 23,462 97.9 
0 0.005 




867 4.4 18,650 95.6 






       Missing Data 0 0.0 216 100.0 
BMI 
       Underweight 
(<18.5 kg/m2) 
108 4.9 2,097 95.1 
0.65 <0.001 
       Normal (>18.5 to 
24.9 kg/m2) 
610 4.3 13,523 95.7 
       Overweight 
(>25.0 to 29.9 kg/m2) 
420 3.4 11,885 96.6 
       Obesity (>30.0 to 
39.9 kg/m2) 
380 3.1 12,063 96.9 
       Extreme Obesity 
(>40 kg/m2) 
120 2.7 4,407 97.3 
       Missing Data 128 2.3 5,524 97.7 
Any Medical Condition 
Yes 1,559 3.5 43,446 96.5 0 0.025 
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No 198 3.4 5,550 96.6 
Unknown 9 2.4 363 97.6 
        Missing Data 0 0.0 140 100.0 
Asthma     
        Yes 483 4.5 10,350 95.5 
0.64 0.043         No/Unknown 1,263 3.2 38,270 96.8 
        Missing Data 20 2.2 879 97.8 
Blood Disorders/Hemoglobinopathy 
        Yes 34 2.3 1,452 96.7 
0.64 0.043         No/Unknown 1,712 3.5 47,168 96.5 
        Missing Data 20 2.2 879 97.8 
Chronic Cardiovascular Disease 
        Yes 606 2.7 21,993 97.3 
0.64 0.043         No/Unknown 1,140 4.1 26,627 95.9 
        Missing Data 20 2.2 879 97.8 
Chronic Liver Disease 
        Yes 437 19.8 1,772 80.2 
0.68 <0.001         No/Unknown 953 2.9 32,225 97.1 
        Missing Data 376 2.4 15,502 97.6 
Chronic Lung Disease 
        Yes 620 4.5 13,200 95.5 
0.64 0.043         No/Unknown 1,126 3.1 35,420 96.9 
        Missing Data 20 2.2 879 97.8 
Chronic Metabolic Disease 
        Yes 484 2.4 19,628 97.6 
0.64 0.043         No/Unknown 1,262 4.2 28,992 95.8 
        Missing Data 20 2.2 879 97.8 
Chronic Renal Disease 
        Yes 234 2.5 9,231 97.5 
0.64 0.043         No/Unknown 1,512 3.7 39,389 96.3 
        Missing Data 20 2.2 879 97.8 
History of Guillain-Barré Syndrome 
        Yes 1 1.4 70 98.6 
0.64 0.042         No/Unknown 1,745 3.5 48,549 96.5 
        Missing Data 20 2.2 880 97.8 
Immunosuppressive Condition 
        Yes 364 4.2 8,314 95.8 
0.64 0.043 
        No/Unknown 1,382 3.3 40,306 96.7 
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        Missing Data 20 2.2 879 97.8 
Neurologic Disease    
        Yes 245 2.4 9,759 97.6 
0.64 0.043         No/Unknown 1,501 3.7 38,861 96.3 
        Missing Data 20 2.2 879 97.8 
Neuromuscular Disorder 
        Yes 51 1.8 2,779 98.2 
0.64 0.043         No/Unknown 1,695 3.6 45,841 96.3 
        Missing Data 20 2.2 879 97.8 
Pregnant (Among Women of Childbearing Age)* 
Yes 42 3.6 1,135 96.7 
0.75 0.003 No/Unknown 204 5.1 3,760 94.9 
Missing Data 72 3.3 2,143 96.7 












of Missing Data 
(PWUD/nPWUD) 
p value 
 N % N % - - 
  1,766 3.4 49,499 96.6 - - 
Survival Status     
Alive 1,716 3.5 47,765 96.5 
0 0.052 
Deceased 50 3.1 1,574 96.9 
Unknown 0 0.0 54 100.0 
Missing Data 0 0.0 106 100.0 
Influenza Subtype    
Influenza A  1,445 3.5 40,295 96.5 
0 NS* 
Influenza B 307 3.3 8,935 96.7 
Influenza 
A&B 
11 6.4 161 93.6 
Influenza A/B 
(not distinguished) 
3 3.7 79 96.3 
Unknown 
Subtype 
0 0.0 29 100.0 
Median LOS in 
Days (IQR) 
3 (2-6) 3 (2-5) 
  
        1 day 214 2.7 7,716 97.3 
0 NS 
        2-3 days 680 3.3 20,159 96.7 
        4-5 days 382 3.7 9,995 96.3 
        6-7 days 196 3.9 4,866 96.1 
        8-14 days 189 3.8 4,817 96.2 
        More than 2 
weeks 
105 5.4 1,856 94.6 
        Missing Data 0 0.0 90 100.0 
ICU Admission       
Yes 398 4.7 8,030 95.3 
0 0.050 
No 1,366 3.2 41,209 96.8 
Unknown 2 1.3 153 98.7 
Missing Data 0 0.0 107 100.0 
Mechanical Ventilation 
Yes 170 5.9 2,731 94.1 
0 0.023         No 1,594 3.3 46,467 96.7 
        Unknown 2 1.3 157 98.7 
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Missing Data 0 0.0 144 100.0 
Sepsis     
        Yes 390 4.6 8,021 95.4 
0.76 NS         No/Unknown 1,342 3.2 40,221 96.8 
        Missing Data 34 2.6 1,257 97.4 
Pneumonia 
        Yes 481 4.3 10,594 95.7 
- - 
        No/Unknown 1,285 3.2 38,905 96.8 
Bacteremia 
        Yes 47 7.2 605 92.8 
0.76 NS         No/Unknown 1,685 3.4 47,635 96.6 
        Missing Data 34 2.6 1,259 97.4 
Received Antiviral Treatment During Hospitalization 
        Yes 1,150 3.6 31,043 96.4 
0.73 NS         No/Unknown 607 3.2 18,111 96.8 
Missing Data 9 2.5 345 97.5 






Tables 3a-c. Analysis of Demographic Characteristics, Risk Factors, and Outcomes Among 
Adults Hospitalized with Laboratory-Confirmed Influenza who Use and Do Not Use Drugs, 
FluSurv-NET, 2016-2017, 2017-2018, and 2018-2019 Seasons 









 N % N % - - 
  1,759 3.8 44,181 96.2 - - 
Influenza Season   
2016-2017  498 28.3 14,170 32.1 - - 








Age      
18-64y 1,535 87.3 18,480 41.8 - - 













        Male 1,013 57.6 19,330 43.8 - - 




Race/Ethnicity       
       White 778 44.2 27,521 62.3 - - 












American Indian or  
Alaska Native 











Table 3b. Risk Factors by Drug Use 





Odds Ratio  
(95% CI) 
p value 
 N % N % - - 
  1,759 3.8 44,181 96.2 - - 
Smoke Tobacco Use     








Never/Unknown 276 15.7 21,814 49.5 - - 
Alcohol Abuse     








        Never/Unknown 1,274 72.4 41,630 94.5 - - 
Received Influenza Vaccine Prior to Hospitalization 
       Received Seasonal 
Influenza Vaccine in 
Corresponding Year 




       Did Not Receive 
Seasonal Influenza Vaccine 
in Corresponding Year 
862 63.0 15,840 42.3 - - 
BMI     
       Underweight (<18.5 
kg/m2) 




       Normal (>18.5 to 24.9 
kg/m2) 
609 37.3 11,811 28.8 - - 
       Overweight (>25.0 to 
29.9 kg/m2) 




       Obesity (>30.0 to 39.9 
kg/m2) 




       Extreme Obesity (>40 
kg/m2) 




Any Medical Condition     




No 194 11.1 3,268 7.5 - - 
Asthma       






        No/Unknown 1,259 72.3 34,641 79.5 - - 
Blood Disorders/Hemoglobinopathy 




        No/Unknown 1,707 98.1 42,515 97.5 - - 
Chronic Cardiovascular Disease 




        No/Unknown 1,135 65.2 22,017 50.5 - - 
Chronic Liver Disease       




        No/Unknown 949 68.5 28,443 94.2 - - 
Chronic Lung Disease       




        No/Unknown 1,121 64.4 30,747 70.5 - - 
Chronic Metabolic Disease 




        No/Unknown 1,257 72.2 24,214 55.5 - - 
Chronic Renal Disease       




        No/Unknown 1,508 86.6 34,481 79.1 - - 
History of Guillain-Barré Syndrome 




        No/Unknown 1,740 99.9 43,532 99.8 - - 
Immunosuppressive Condition 




        No/Unknown 1,378 79.2 35,687 81.9 - - 
Neurologic Disease       




        No/Unknown 1,496 85.9 34,714 79.6 - - 
Neuromuscular Disorder       




        No/Unknown 1,690 97.1 41,021 94.1 - - 
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Pregnant (Among Women of Childbearing Age)* 




No/Unknown 274 87.0 3,612 76.4 - - 














 N % N % - - 
  1,759 3.8 44,181 96.2 - - 
Survival Status     
Alive 1,709 97.2 42,479 96.5 - - 




LOS (Days)       
        1 day 211 12.0 6,208 14.1 - - 




















ICU Admission       




No 1,362 77.5 37,069 84.4 - - 
Mechanical Ventilation       




        No 1,589 90.4 41,443 94.4 - - 
Sepsis       




        No/Unknown 1,336 77.5 35,145 81.7 - - 
Pneumonia       




        No/Unknown 1,280 72.8 34,505 78.1 - - 
Bacteremia       






        No/Unknown 1,678 97.3 42,430 98.7 - - 
Received Antiviral Treatment During Hospitalization 




        No/Unknown 604 34.5 15,909 36.3 - - 
*Risk ratios were calculated for death, LOS, ICU admission, mechanical ventilation. An odds 





Table 4. Analysis of Specific Substances Among Adults Hospitalized with Laboratory-
Confirmed Influenza who Use and Do Not Use Drugs, FluSurv-NET, 2017-2018 and 2018-
2019 Seasons 
 
Specific Drug Use Current Drug Use 





 N % N % - - 
 1,261 4.0 30,011 96.0 - - 
Marijuana       




        No/Unknown 919 72.9 28,833 96.1 - - 
E-Cigarettes       











Table 5. Cochran–Mantel–Haenszel Stratified Analysis to Control for the Confounding 
Effect of Age on Outcomes and Risk Factors of Interest Among Adults Hospitalized with 










































*Children under 18 years old were excluded. Risk ratios were calculated for death, ICU 








Table 6a.i. Multivariable Logistic Regression Model of Factors Associated with DEATH Among 
Adults Hospitalized with Severe Influenza with Non-missing Data, All Seasons (N=24,615) 
 
Adjusted Odds 
Ratio (95% CI) 
p value 
Age   
        18y-64y  - - 




































Table 6a.ii. Multivariable Logistic Regression Model of Factors (Not Including Underlying Medical 
Conditions) Associated with DEATH Among Adults Hospitalized with Severe Influenza with Non-
missing Data, All Seasons (N=24,615) 
 
Adjusted Odds 
Ratio (95% CI) 
p value 
Age   
        18y-64y  - - 




















Received Seasonal Influenza 







Table 6b. Multivariable Logistic Regression Model of Factors Associated with ICU 
ADMISSION Among Adults Hospitalized with Severe Influenza with Non-missing Data, 






Age   
        18y-64y  - - 












Race/Ethnicity   
       White - - 





















Received Seasonal Influenza 

















Table 6c. Multivariable Logistic Regression Model of Factors Associated with 
MECHANICAL VENTILATION Among Adults Hospitalized with Severe Influenza with 











Received Seasonal Influenza 

















Table 6d. Multivariable Logistic Regression Model of Factors Associated with 
VACCINATION Among Adults Hospitalized with Severe Influenza with Non-missing 






Age   
        18y-64y  - - 












Race/Ethnicity   
       White - - 

















Smoke Tobacco Use   








        Never  - - 
Alcohol Abuse   



























Table 6e. Multivariable Logistic Regression Model of Factors Associated with 
ANTIVIRAL TREATMENT Among Adults Hospitalized with Severe Influenza with Non-






Season   
        2016-2017 - - 
















Figure 1. Distribution of PWUD Cases Hospitalized with Laboratory-Confirmed Influenza by Site, FluSurv-NET, 2016-2017, 






































Percentage of People Who Use Drugs (PWUDs), By Site
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Figure 2. Specific Classes of Drug Use Among All PWUD Cases Hospitalized with Laboratory-Confirmed Influenza, FluSurv-

























Specific Drug Use, 2017-18 and 2018-19 Seasons Only
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Figure 3. Hallucinogen Use Among PWUD Cases Hospitalized with Laboratory-Confirmed Influenza by Site, FluSurv-NET, 



















































Hallucinogen Use Among People Who Use Drugs, By Site
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Figure 4. Stimulant Use Among PWUD Cases Hospitalized with Laboratory-Confirmed Influenza by Site, FluSurv-NET, 

































































Stimulant Use Among People Who Use Drugs, By Site
Overall Stimulant Use Cocaine/Crack Use
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Figure 5. Opioid Use Among PWUD Cases Hospitalized with Laboratory-Confirmed Influenza by Site, FluSurv-NET, 2017-
2018 and 2018-2019 Seasons 

































































Opioid Use Among People Who Use Drugs, By Site
Overall Opioid Use Heroin Use
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Figure 6. Depressant Use Among PWUD Cases Hospitalized with Laboratory-Confirmed Influenza by Site, FluSurv-NET, 












































Depressant Use Among People Who Use Drugs, By Site
